All In Biotech

BLA 761234 · Bristol Myers Squibb

Opdualag

Nivolumab, Relatlimab-Rmbw · Intravenous · Programmed Death Receptor-1 Blocking Antibody; Lymphocyte Activation Gene-3 Blocker

NovelPriority reviewOrphan

CDER novel approval, Mar 18, 2022: To treat unresectable or metastatic melanoma

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Mar 18, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,779

188 Phase 3, 304 recruiting

FAERS reports

515

342 serious, 107 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 8, 2026.

OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (1)

Mechanism: Relatlimab is a human IgG4 monoclonal antibody that binds to the LAG-3 receptor, blocks interaction with its ligands, including MHC II, and reduces LAG-3 pathway-mediated inhibition of the immune response. Antagonism of this pathway promotes T cell proliferation and cytokine secretion. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors....

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OPDUALAG · NIVOLUMAB 240MG; RELATLIMAB-RMBW 80MG · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nivolumab" as an intervention, any sponsor and status, largest first.

All 1,779 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death76
  • off label use60
  • malignant neoplasm progression35
  • fatigue19
  • myocarditis19
  • product storage error19
  • product dose omission issue15
  • adverse event13
  • colitis13
  • rash13
  • diarrhoea12
  • myasthenia gravis12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
202246
2023111
2024106
2025134
2026117

Recalls

1 FDA enforcement reports for this application.

  • Oct 21, 2025 · Class II · Ongoing

    Lack of Assurance of Sterility.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Opdualag (Nivolumab-Relatlimab-Rmbw)

2024 spending

$5.3M

Beneficiaries

34

183 claims

Per beneficiary

$156,495

$722.94 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,990,655
2023$4,305,352
2024$5,320,815

Part B: Opdualag (Nivolumab-Relatlimab-Rmbw) · HCPCS J9298

2024 spending

$362M

Beneficiaries

2,535

13,021 claims

Per beneficiary

$142,849

2024 ASP limit $188.78 per unit

View as table
YearSpending
2020$0
2021$0
2022$42,513,402
2023$253,917,665
2024$362,121,215

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,745 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.